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Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der J. W. Goethe-Universita¨t, Theodor-Stern-Kai 7, 60590 Frankfurt amMain, GermanyTreatment predictors are important tools for the management of therapy in patients with chronic hepatitis B and C virus
(HBV, HCV) infection. In chronic hepatitis B, several pretreatment parameters have been identiﬁed for prediction of viro-
logic response to interferon alfa-based antiviral therapies or treatment with polymerase inhibitors. In interferon alfa and
pegylated interferon alfa-treated patients, low baseline HBV DNA concentrations, HBV genotype A (B), and high baseline
ALT levels are signiﬁcantly associated with treatment response. In patients treated with nucleos(t)ide analogues, low base-
line HBV DNA but not viral genotype is positively associated with virologic response. During treatment the best predictor
of response is HBV DNA kinetics. Early viral suppression is associated with favourable virologic response and reduced risk
for subsequent resistance mutations. For the current standard treatment with pegylated interferon alfa and ribavirin in
patients with chronic hepatitis C, infection with HCV genotypes 2 and 3, baseline viral load below 400,000–
800,000 IU/ml, Asian and Caucasian ethnicity, younger age, low GGT levels, absence of advanced ﬁbrosis/cirrhosis,
and absence of steatosis in the liver have been identiﬁed as independent pretreatment predictors of a sustained virologic
response. After initiation of treatment, initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR)
is the best predictor of sustained virologic response independent of HCV genotype.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V.
Keywords: Predictors; HBV; HCV; Sustained virologic response
Open access under CC BY-NC-ND license.1. Introduction
Chronic infection with either hepatitis B or hepatitis
C viruses (HBV and HCV) is associated with substantial
morbidity and mortality worldwide. More than 400 mil-
lion people are infected with hepatitis B despite the exis-
tence of a potent vaccine for more than 25 years [1,2]
and approximately 170 million people are estimated to
be infected with the hepatitis C virus [3–5]. Long-term0168-8278 2008 European Association for the Study of the Liver. Publish
doi:10.1016/j.jhep.2008.07.013
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E-mail address: sarrazin@em.uni-frankfurt.de (C. Sarrazin).complications of both diseases are liver cirrhosis and
the risk of developing hepatocellular carcinoma [6].
In patients with chronic hepatitis B, persistent viral
replication is associated with progression of liver dis-
ease and treatment is aimed at maximal viral suppres-
sion. In hepatitis B e-antigen (HBeAg) positive
chronic hepatitis B, spontaneous or treatment-induced
clearance of HBeAg and seroconversion to anti-HBe is
typically followed by a long-term period of low-level
replication, which may be termed sustained virologic
response (SVR). In HBeAg-negative patients the aim
of antiviral treatment is a virologic and biochemical
response with undetectable or suppressed HBV DNA
and normalization of aminotransferase levels. After
termination of antiviral therapy in HBeAg-negative
patients, a relapse within diﬀerent periods of time is
commonly observed. This makes it diﬃcult to establish
a deﬁnition of sustained virologic response for theseed by Elsevier B.V. Open access under CC BY-NC-ND license.
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ative patients, HBsAg seroconversion to anti-HBs
would be the best deﬁnition of an SVR. However this
is only rarely achieved, either spontaneously or treat-
ment-induced.
For many years, interferon (IFN) alfa was the only
treatment speciﬁcally approved for patients with chronic
hepatitis B by regulatory authorities [7–9]. However,
over the last few years, considerable progress has been
made in terms of development of new and potent
nucleoside and nucleotide analogues that directly inhibit
viral replication. Pretreatment predictors of virologic
response in patients with chronic hepatitis B are impor-
tant tools for selection of optimal antiviral therapy with
either interferon alfa or nucleos(t)ide analogues and ini-
tial HBV DNA kinetics during therapy may be used for
prediction of long-term virologic response.
In chronic hepatitis C, the primary therapeutic goal
is SVR, deﬁned as undetectable HCV RNA by a sensi-
tive assay at the end of a 24-week follow-up period after
treatment completion. The current combination therapy
consisting of pegylated (PEG) IFN plus ribavirin
(RBV) for at least 16–48 weeks may be accompanied
by numerous potentially dose-limiting side eﬀects and
SVR rates are still unsatisfactory with only approxi-
mately 50% [6,10–13]. Over the past years a large num-
ber of studies have identiﬁed viral- and patient-related
factors for pretreatment prediction of the probability
of a sustained virologic response. Furthermore, after
initiation of antiviral therapy HCV RNA viral kinetics
can be used for prediction of virologic response and
measurement of HCV RNA at diﬀerent time points is
used for tailoring treatment duration in patients with
chronic hepatitis C.2. Methods
A systematic literature search using electronic and citation dat-
abases (PubMed and Web of Science) from 1990 to June 2008 was per-
formed to identify English-language articles based on predictors of
sustained virologic response in chronic hepatitis B and chronic hepati-
tis C by using the following terms and keywords alone and/or in
appropriate combinations: chronic hepatitis B, HBV DNA, antiviral
therapy, predictors, baseline parameters, treatment response, sustained
virologic response, HBsAg, HBeAg loss, seroconversion, interferon
alfa, pegylated interferon alfa, nucleos(t)ide analogues, lamivudine,
adefovir, entecavir, telbivudine, tenofovir; chronic hepatitis C, HCV-
RNA, interferon alfa, pegylated interferon alfa, ribavirin, and
genotype.
In addition, relevant web sites and conference abstract books of the
American Association for the Study of Liver Diseases (AASLD) and
the European Association for the Study of the Liver (EASL) were
searched for conference proceedings and abstracts (2005-June 2008).
Reference lists of all identiﬁed articles and reviews were checked for
relevance. Prospective and retrospective analyses of large multicenter
studies were included and results from smaller, non-randomized,
open-label studies have been accepted, if these studies were performed
with adequate methodology as critically reviewed and evaluated by the
authors.
Finally, only trials regarding ﬁrst-line therapies and no re- or add-
on-treatment studies were considered for this evaluation.3. Hepatitis B
To date, information on predictors of response to
treatment of chronic hepatitis B is limited. This is owed,
in part, to the heterogeneity of treatment options. Until
recently, standard IFN and lamivudine (LAM) were the
only approved drugs for use within the European Union
and elsewhere [8,9,14–21]. However, more recent inves-
tigations have led to current drug approvals, including
PEG IFN alfa-2a as well as the nucleos(t)ide analogues
adefovir dipivoxil (ADV), entecavir (ETV), telbivudine
(LdT), and tenofovir disoproxil fumarate (TDF) [22–
32]. Furthermore, the nucleoside analogue clevudine
(CLD) is approved in South Korea [33,34].
In addition, deﬁnitions of treatment eﬃcacy and
treatment endpoints continue to vary signiﬁcantly
between clinical trials and are not easily correlated. This
issue has been addressed recently and suggestions for a
more standardized approach have been made [35].
The ultimate goal in the treatment of chronic hepati-
tis B is the prevention of liver cirrhosis and its sequelae,
including hepatocellular carcinoma (HCC).
Since HBsAg seroconversion is rarely achieved, cur-
rent treatment concepts are aimed at (i) sustained sup-
pression of viral replication, (ii) normalization of
aminotransferase levels, (iii) histologic improvement,
and, in the case of hepatitis B e-antigen (HBeAg) posi-
tive disease, (iv) HBeAg loss or seroconversion to anti-
HBe. As a standardized deﬁnition of sustained response
is not available, treatment endpoints vary greatly
between diﬀerent trials. However, despite the lack of
comparable data, a number of baseline and on-treat-
ment predictors of virologic response to therapy in
chronic hepatitis B have been identiﬁed and will be
reviewed below.
3.1. Baseline predictors
A number of potential baseline predictors may have
an impact on antiviral treatment outcome. Among
these are demographic (ethnicity, patient age, gender,
body weight, duration of infection, alcohol, and/or
drug abuse), histologic (grading of necroinﬂammatory
activity, staging of liver ﬁbrosis, presence of liver
steatosis), virologic (baseline HBV DNA levels, HBeAg
status, HBV genotype, genetic polymorphisms), and
biochemical parameters (baseline aminotransferase
levels) (Table 1).
In addition, coinfection with HIV is regarded to be
associated with poorer response rates. This also applies
to HCV/HIV-coinfection [36–43].
3.1.1. Demographic parameters
HBeAg-positive disease.
Ethnicity. Univariate but not multivariate analysis
revealed that Asian patients were less likely to experi-
Table 1
Baseline predictors of response to antiviral therapy in chronic hepatitis Ba
Baseline predictors HBeAg positiveb HBeAg negativec
(PEG) IFN NUC (PEG) IFN NUC
Demographic factors
Ethnicity No correlation [9,46,49] No correlation [44,45,47,48] No correlation [53] No correlation [47,48,53]
Age, gender No correlation [46,49] Conﬂicting data [44,47,50,52] Younger age,
female gender [53]
Younger age,
female gender [53]
Histologic factors
Grading High necroinﬂammatory
activity [9,54–58]
Conﬂicting data [44,47] No correlation [53] No correlation [47,53]
Staging Advanced ﬁbrosis [55] No (marginal) correlation
[44,47,55,59]
No data No correlation [47]
Hepatic steatosis Insuﬃcient data Insuﬃcient data No data No data
Virologic factors
HBV DNA Low baseline VL
[9,54,57,66–70]
Low baseline VL [44,47,59,71,72] Low baseline VL [53] Low baseline VL [47,53,72]
HBeAg levels Correlation [70,73] No data No data No data
Genotype A > D or C;B > C
[31,69,76–79,88]
Conﬂicting data, generally
no correlation [72,80–87]
B + C > D in PEG IFN-2a
+/LAM [53]
No correlation [72,86,87]
Biochemical parameters
Serum ALT levels High baseline ALT
levels [31,66,68,69]
Conﬂicting data
[44,47,59,72,87,90]
High baseline ALT levels [53] Conﬂicting data
[47,53,72,87,90]
a Based on multivariate analysis.
b Response deﬁned as HBeAg loss or seroconversion.
c Response deﬁned as HBV DNA suppression at the end of treatment or a deﬁned follow-up period; VL, viral load.
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four diﬀerent trials involving IFN, LAM, placebo or the
combination of IFN plus LAM treatment [44]. In other
studies involving IFN, PEG IFN alfa-2a or therapy with
nucleos(t)ide analogues, ethnicity was not found to be a
signiﬁcant predictor of virologic response [9,45–49].
Age/gender/other factors. Other demographic factors,
including age, gender, intravenous drug abuse, and
duration of HBsAg positivity did not aﬀect treatment
outcome, deﬁned as HBeAg loss, in an analysis of 10
controlled trials of IFN therapy [46]. In patients trea-
ted with PEG IFN alfa-2a plus LAM vs. LAM alone,
age had no and gender had only marginal eﬀect on
HBeAg seroconversion [49]. Age, however, was found
to be an independent predictor of HBeAg seroconver-
sion and loss of HBV DNA in patients treated with
LAM in one study [50], while Perrillo et al. did not ﬁnd
a favourable association between patient age, gender,
body weight or BMI and HBeAg loss during LAM
treatment [44]. In addition, gender did not inﬂuence
the performance of ETV, assessed by histologic
improvement and sustained virologic suppression [52].
Finally, stepwise logistic regression analysis revealed
lower body weight to be an important predictor of
HBV DNA suppression to <400 copies/ml (80 IU/
ml) at week 48 in patients treated with ADF [47]. No
data were available on potential demographic baseline
predictors aﬀecting treatment outcome in other
nucleos(t)ide agents.HBeAg-negative disease.
Ethnicity/age/female gender. Little has been published
on demographic pretreatment predictors in HBeAg-neg-
ative disease. Ethnicity (Asian vs. Caucasian) was nei-
ther predictive of HBV DNA <400 copies/ml (80 IU/
ml) at week 48 of ADF treatment [47], nor was it asso-
ciated with combined histologic and/or virologic and
biochemical response to ETV and PEG IFN alfa-2a
and/or LAM therapy, respectively [48,53]. However,
younger age and female gender were signiﬁcantly
associated with treatment response in the latter study.
3.1.2. Histologic parameters
HBeAg-positive disease.
Grading. The intensity of necroinﬂammatory activity
as assessed by histological grading scores has been pro-
ven to be positively associated with sustained response
to IFN treatment [9,54–57]. However, most of the older
studies referred to Knodell’s histological activity index
(HAI), which encompasses both grading (necroinﬂam-
matory activity) and staging (ﬁbrosis) scores. Thus, on
a retrospective basis, a clear diﬀerentiation between
these two factors is diﬃcult. A high necroinﬂammatory
activity score was also predictive of response to treat-
ment with PEG IFN alfa-2b [58]. Nucleos(t)ide studies
yielded conﬂicting data. Whereas Perrillo et al.
concluded that high necroinﬂammatory activity was
amongst the most important predictors of HBeAg loss
in LAM-treated patients [44], such a correlation was
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the grading score as a treatment predictor in other
nucleos(t)ide analogues are currently not available.
Staging. The staging score (degree of ﬁbrosis/cirrho-
sis) as a separate determinant was also noted to be a pre-
dictor of IFN response [55]. In LAM and ADF-treated
patients, no or only marginal eﬀects of staging (ﬁbrosis)
scores or cirrhosis on sustained response rates were seen
by univariate and multivariate analyses [44,47,55,59].
Again, no data were available on other nucleos(t)ides.
Hepatic steatosis. Despite the high prevalence of
hepatic steatosis in patients with chronic hepatitis B
[60,61], its impact on response to antiviral treatment
has been poorly studied. In a retrospective, single centre
cohort analysis no association between steatosis and
response to antiviral treatment with either PEG IFN
alfa-2a or the combination of PEG IFN alfa-2a plus
LAM was observed [62].
HBeAg-negative disease.
Grading/staging. Few studies have looked at grading
scores as a predictive variable of treatment response in
HBeAg-negative disease. No correlation was found
between HAI score and combined biochemical and
virologic response in PEG IFN alfa-2a and/or LAM
treatment [53]. In addition, necroinﬂammatory activity
and ﬁbrosis score were not predictive of HBV DNA
suppression when ADF was given [47].
3.1.3. Virologic parameters
HBV DNA viral load levels are strongly associated
with disease progression to liver cirrhosis and HCC
[63,64]. In addition, virologic parameters are also recog-
nised as independent predictors of treatment response,
when assessed before initiation of therapy. However,
clinical trials may not be readily comparable due to
the lack of a standardized deﬁnition of HBV DNA
response and standardized quantiﬁcation of HBV
DNA. For HBV DNA quantiﬁcation, many of the older
studies used hybridization-based assays with detection
limits of around 105 copies/ml and with the introduction
of a HBV DNA standard and real-time PCR-based
assays, suﬃcient comparability between assays, and
intra- and interassay precision as well as reproducibility
has only recently become available [35,65].
HBeAg-positive disease.
HBV DNA viral load. Low baseline serum HBV
DNA levels have been shown to be independently asso-
ciated with higher rates of HBeAg/anti-HBe seroconver-
sion in a number of studies involving conventional IFN
treatment [9,54,57,66–68]. This was later conﬁrmed in
PEG IFN-treated patients by multivariate analyses
[69,70]. Low baseline HBV DNA levels were also predic-
tive of HBeAg loss or seroconversion in patients receiv-
ing LAM or LdT [44,59,71,72]. In addition, whenadefovir was given, low baseline HBV DNA was associ-
ated with sustained viral suppression, deﬁned as HBV
DNA <400 copies/ml at week 48 [47].
HBeAg levels. Measurement of HBeAg levels may
additionally be useful to predict seroconversion not only
during but also before antiviral therapy with PEG IFN
alfa-2a, as was recently proposed [70,73]. Patients with
low HBeAg levels were more likely to achieve serocon-
version compared to patients with high baseline HBeAg
levels. No data are available for treatment with nucle-
os(t)ide analogues.
Genotype. The role of genotype as a treatment predic-
tor in chronic hepatitis B has not been as clearly deﬁned
as in chronic hepatitis C and remains controversial.
However, there is increasing evidence that HBV geno-
type may be an important and independent predictor
of response to IFN-based treatment, and genotyping
has become a frequent diagnostic tool when IFN ther-
apy is being considered [69,74,75]. In IFN and PEG
IFN-treated patients, HBV genotype A was associated
with signiﬁcantly higher rates of HBeAg loss or even
HBsAg clearance when compared to HBV genotype D
or C [31,69,76–78]. In addition, HBV genotype B-
infected patients were more likely to achieve HBeAg
clearance when compared to HBV genotype C [69,79].
With LAM, the role of HBV genotypes remains contra-
dictory [80–84]. Furthermore, most nucleos(t)ide studies
suggest that the treatment response (deﬁned as HBeAg
loss or seroconversion and HBV DNA reduction to
<400 copies/ml, respectively) is the same across diﬀerent
genotypes [72,85–87].
HBeAg-negative disease.
HBV viral load. In accordance with the results in
HBeAg-positive patients, lower baseline HBV DNA
was also an important predictor of combined virologic
and biochemical response at 24 weeks post-treatment
in HBeAg-negative patients in one study involving both
PEG IFN and/or LAM-treated patients [53]. In addi-
tion, low baseline viral load was predictive of end-of-
treatment viral suppression in both ADF and LdT-
treated patients [47,72].
HBV genotype. Patients with genotypes B or C were
more likely to achieve combined response (ALT normal-
ization and HBV DNA <20,000 copies/ml [4000 IU/
ml]) at 24 weeks post-treatment than genotype D when
treated with LAM and/or PEG IFN alfa-2a [53].
Among HBV genotypes A–D, no diﬀerence was noted
with respect to histological and virological treatment
outcomes in patients treated with other nucleos(t)ides
[72,86,87].
3.1.4. Biochemical parameters
HBeAg-positive disease.
Serum ALT. High pretreatment serum alanine trans-
aminase (ALT) levels are associated with increased rates
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treated patients [31,66,68,69,89]. This was also con-
ﬁrmed for LAM treatment where the rate of HBeAg loss
was particularly high if ALT levels were greater than 5
times the upper limit of normal (ULN) [44,59]. In addi-
tion, >2 ULN were signiﬁcantly predictive of HBeAg
seroconversion in the LdT registration trial [72]. How-
ever, for histologic improvement and/or reduction of
HBV DNA to <400 copies/ml (80 IU/ml) no associa-
tion between baseline ALT levels and treatment
response was noted in ADF and ETV-treated patients
[47,87,90].
HBeAg-negative disease.
Serum ALT. As in HBeAg-positive disease, high
baseline ALT levels were signiﬁcantly associated with
response to PEG IFN alfa-2a and/or LAM treatment
when assessed by multivariate analysis [53]. Again, high
ALT levels >5 ULN were the strongest predictor of
combined response (ALT normalization, HBV DNA
suppression) at 24 weeks post-treatment. There was only
limited information on whether ALT levels inﬂuence
other nucleos(t)ide treatment regimens. However, it
was noted that baseline ALT levels had a less pro-
nounced or no eﬀect on virologic responses irrespective
of compound [47,72,87,90].
3.2. Predictors during antiviral therapy
3.2.1. Viral load monitoring
Suppression of serum HBV DNA appears to be the
most important on-treatment predictor of virologic
response in chronic hepatitis B [71,91]. This evidence
ﬁnds support in a number of studies reviewed below
and frequent on-treatment monitoring of HBV DNA
levels has been established as a tool in the management
of chronic hepatitis B [1,92]. From the various sources
available, it remains unclear which time points during
therapy and which cut-oﬀs of HBV DNA levels may
be used in clinical practice for monitoring and potential
adjustment of antiviral therapy. However, early identiﬁ-
cation of patients at risk of developing drug resistance
may become a key issue in the management of patients
treated with nucleos(t)ides [92–94].
HBeAg-positive disease.
HBV viral load. In patients treated with conventional
IFN, on-treatment reduction of HBV DNA levels was
associated with overall improved clinical outcomes
[95–97]. In a large randomized multicenter study of
PEG IFN alfa-2b with or without LAM, a 1 log10 drop
in serum HBV DNA levels at week 32 of PEG IFN
alfa-2b monotherapy was predictive of HBeAg loss in
genotype A patients only. Earlier predictions were not
suﬃciently associated with sustained response in this
study [98]. Overall, patterns of viral decline werevariable and prediction of response proved to be
diﬃcult. In LAM-treated patients, early suppression of
viral load was linked to greater rates of HBeAg serocon-
version, even when advanced liver disease was present
[99,100]. In addition, it was demonstrated that a drop
in viral load to HBV DNA levels below 2000 IU/ml at
week 4 could predict an ideal outcome, deﬁned as com-
bined virological and biochemical response at year 5
[100]. Furthermore, complete viral response (HBV
DNA <69 IU/ml) at week 24 was positively associated
with week 48 and week 72 response to TDF [23]. Finally,
in patients treated with LdT and LdT or ADF, maximal
reduction of HBV DNA levels at week 24 were signiﬁ-
cantly associated with week 104 and week 52 eﬃcacy
endpoints, respectively (ALT normalization, PCR-nega-
tivity, HBeAg seroconversion) [28,101–103].
Resistance. To date, there have been several studies
addressing the signiﬁcance of early viral suppression to
reduce the risk of resistance to nucleos(t)ide analogues.
The time at which complete viral suppression must be
achieved varies by the compound. Greater early (12-
or 24-week) HBV DNA reduction was associated with
reduced risk for subsequent LAM resistance [100,104–
106]. In a randomized controlled study comparing the
eﬃcacy of LdT with LAM, incomplete viral suppression
at 24 weeks of therapy was found to be predictive of
subsequent resistance in patients in either treatment
arm [28]. In addition, HBV DNA levels at 1 year were
predictive of ADF resistance at 3 years [107]. Thus, it
appears that nucleos(t)ide analogues with a lower
genetic barrier to resistance (LAM, LdT) must achieve
viral suppression more rapidly than those agents with
higher barriers to resistance (ADF, ETV, TDF).
HBeAg levels. Measurement of HBeAg levels during
antiviral therapy may provide additional information
to evaluate the response (HBeAg seroconversion) to
PEG IFN alfa-2a therapy. Indeed, after 24 weeks of
treatment, high levels of HBeAg had a greater negative
predictive value (96%) than that obtained for HBV
DNA levels at the same time point (86%) [73].
HBeAg-negative disease.
HBV viral load. In patients treated with PEG IFN
alfa-2a, HBV DNA reductions to <400 copies/ml
(80 IU/ml) at week 12 were signiﬁcantly associated
with sustained ALT normalization and HBV DNA
<20,000 copies/ml (4000 IU/ml) at 24 weeks after the
end of therapy [108]. In addition, HBV DNA levels of
less than 2.5 log10 copies/ml at week 12 had a positive
predictive value of 64% to achieve week 72 response.
However, since the negative predictive value was just
70%, decisions on early treatment discontinuation may
not be made on the basis of these ﬁndings. As in
HBeAg-positive disease, viral load at week 24 was the
most important predictor of 1-year eﬃcacy outcomes
in LdT-treated patients [109] and complete viral
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dictive of complete week 48 and week 72 TDF response
[22].
Resistance. Comparable to the situation in HBeAg-
positive patients again, the time point at which HBV
DNA must be negative to avoid the development of
resistance seems to vary by compound. Baseline HBV
DNA levels >106 copies/ml were predictive of viral
breakthrough in patients receiving LAM-treatment
[110]. In a study involving both HBeAg-positive and -
negative patients, persistent viraemia at 6 months was
independently associated with early development of
LAM resistance [84]. In the GLOBE trial viral load at
week 24 of therapy was a predictor of viral break-
through and resistance for treatment with either LAM
or LdT [28]. In ADF-treated patients, changes in HBV
DNA levels at week 4 and 12 did not predict resistance
at week 144 [107]. However, in a stepwise logistic regres-
sion model, detectable serum HBV DNA at week 48 was
a signiﬁcant predictor of ADF-resistance over 192 weeks
[111].4. Hepatitis C
The aim of treatment in chronic hepatitis C is to
achieve a sustained virologic response (SVR) deﬁned
as undetectable HCV RNA with a sensitive PCR assay
(<50 IU/ml) 24 weeks after the end of antiviral therapy.
In patients who achieved an SVR following standard
interferon (IFN)-based antiviral therapy, virological
relapse after 5 years of follow-up was observed in 2–
4% only, and no relapse was reported after 5–10 years
[112]. Moreover, the 5-year durability of an SVR was
in excess of 99% in patients treated with pegylated
(PEG) IFN [113–116].
A number of host and viral factors have been identi-
ﬁed that inﬂuence treatment outcomes.
4.1. Baseline predictors
4.1.1. Demographic parameters
Ethnicity. Among the diﬀerent demographic parame-
ters, ethnicity is a well studied host factor that is closely
associated with treatment response [117] (Table 2).
In several controlled trials it was demonstrated that
African-American patients have a reduced likelihood
of SVR compared to non-African-Americans. Sustained
response rates for African-Americans ranged from 8%
to 23% for treatment with IFN plus RBV [118,119] to
19–28% for therapy with PEG IFN plus RBV [120–
122] in comparison to 22–42% and 39–52%, respectively,
for non-African-Americans. The poor response rates
have been attributed by some to higher body weight
and a higher prevalence of genotype 1 infection among
African-Americans [118]. However, studies with highernumbers of black patients and treatment with (PEG)-
IFN plus RBV for 48 weeks clearly showed signiﬁcantly
lower SVR rates in comparison with white patients for
genotype 1 infection, while no diﬀerence was observed
for other genotypes [118,119,121,122] (Table 2).
Although not as intensively studied, Latinos (Hispanics)
also tended to have poorer SVR rates compared to Cau-
casian patients [118,123–125]. Finally, HCV infected
individuals of Asian origin seem to achieve better SVR
rates in comparison to Caucasians [123,126]. In a recent
retrospective analysis of a large multicenter study Asian
treatment-naı¨ve patients with genotypes 1–3 infection
showed a response rate of 65% when treated with PEG
IFN alfa-2a plus RBV in comparison to an SVR rate
of 45% in the Caucasian study arm [126] (Table 2).
The mechanism by which race inﬂuences antiviral treat-
ment response remains, however, unclear and the poten-
tial underlying immunogenetic pathways have yet to be
discovered.
Gender. A large analysis (n = 1744) of two trials
involving standard IFN plus RBV therapy showed a sig-
niﬁcant positive correlation between female gender and
SVR (p < 0.004) [127]. However, although on univariate
analyses a signiﬁcant negative correlation between male
gender and SVR was found in both PEG IFN registra-
tion trials, no statistically signiﬁcant correlation was
found on multivariate analyses [6,10]. In the PEG
IFN2b/RBV trial sex was no longer signiﬁcant when
weight was taken into account (Table 2).
Age. In all large prospective studies of (PEG) IFN and
RBV combination therapy younger age correlated signif-
icantlywith anSVRwhen assessed by univariate andmul-
tivariate analyses and patients younger than 40–45 years
showed the best response rates [6,10,12,127] (Table 2).
Obesity/body weight. Obesity is a predictor of disease
progression in patients with chronic hepatitis C. In a
prospective trial, a body mass index (BMI) of P25 kg/
m2 was signiﬁcantly associated with ﬁbrosis progression
[128]. A high BMI but not body weight was also inver-
sely correlated with SVR in both IFN and PEG IFN-
treated individuals [129,130]. Furthermore, in both,
PEG IFN alfa-2a and PEG IFN alfa-2b combination
therapy with RBV, a lower baseline body weight
(675–80 kg) was signiﬁcantly associated with achieving
an SVR across all genotypes [6,10,12,130]. However,
this was not conﬁrmed in other large studies with
PEG/RBV combination therapy in HCV genotypes 1–
3-infected patients in which multilogistic regression
analyses including BMI and body weight were con-
ducted [13,131] (Table 2).
Alcohol consumption. Limited data are available on
the impact of alcohol on antiviral treatment outcome
Table 2
Baseline predictors of SVR in chronic hepatitis C: demographic factorsa
Baseline predictors Number of patients Genotype Single
p-value
Odds ratiob Therapy Reference
Ethnicity
White > Black 1744 1–6 n.s. No data IFN 2b/IFN 2b + RBV Mc Hutchison et al. [118]
200 1 <0.001 No data PEG IFN 2b + RBV Muir et al. [121]
401 1 <0.0001 1.96 (1.48–2.60) PEG IFN 2a + RBV Conjeevaram et al. [122]
Caucasian, Asian,
Latino vs. Black
4913 1,2,3 <0.0001 2.41–3.70 PEG IFN 2b + RBV Jacobson et al. [131]
Black < non-Black 785 1 <0.03 0.45 (0.22–0.93) IFN 2b + RBV Brau et al. [119]
Asian > Whites 405 1,2,3 0.02 2.22 (1.11–4.46) PEG IFN 2a + RBV Missihia et al. [126]
Asian 597 1,2,3 No data 2.9 (1.3–6.2) IFN 2b + RBV Hepburn et al. [123]
Non-Latino
Caucasians > Latinos
569 1 <0.0001 No data PEG IFN 2a + RBV Rodriguez-Torres et al. [125]
Gender
Female 1744 1–6 0.004 1.5 (1.1–1.9) IFN/IFN 2b + RBV Poynard et al. [127]
1530 1–6 n.s. No data IFN 2b + RBV/PEG
IFN 2b + RBV
Manns et al. [6]
1121 1–6 n.s. No data PEG IFN 2a+/RBV/
IFN 2b + RBV
Fried et al. [10]
Age
Younger age 1530 1–6 <0.0001 No data IFN 2b + RBV/PEG
IFN 2b + RBV
Manns et al. [6]
640 years 1744 1–6 0.005 1.4 (1.1–1.9) IFN/IFN 2b + RBV Poynard et al. [127]
1121 1–6 <0.001 2.60 (1.72–3.95) PEG IFN 2a+/RBV/
IFN 2b + RBV
Fried et al. [10]
645 vs. >45 years 1463 2,3 0.002 1.5 (1.17–1.93) PEG IFN 2a + RBV Shiﬀman et al. [12]
Body weight/BMI
Lower weight 1530 1–6 <0.0001 No data IFN 2b + RBV/PEG
IFN 2b + RBV
Manns et al. [6]
675 kg 1121 1–6 0.002 1.91 (1.27–2.89) PEG IFN 2a+/RBV/
IFN 2b + RBV
Fried et al. [10]
Lower BMI 455 1 <0.05 No data PEG IFN 2a + RBV Berg et al. [130]
680 kg vs. >80 kg 1463 2,3 <0.001 1.75 (1.37–2.24) PEG IFN 2a + RBV Shiﬀman et al. [12]
Body weight 224 2,3 n.s. No data PEG IFN 2b + RBV Zeuzem et al. [13]
4913 1,2,3 n.s. No data PEG IFN 2b + RBV Jacobson et al. [131]
a Based on multivariate analysis.
b 95% conﬁdence interval; n.s., not statistically signiﬁcant.
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spective analyses. However, a dose-dependent decrease
of response to standard IFN has been suggested [132].
In another large, prospective multicenter trial it was
observed that patients who drink alcohol discontinue
therapy more often and therefore achieve lower SVR
rates. Individuals with alcohol consumption who ﬁn-
ished treatment had comparable response rates to non-
drinkers [133].
Genetic diversity. Several studies have investigated
host genetic patterns that may be associated with the
likelihood of virologic response or non-response to
IFN-based therapy. Research on hepatic tissue suggests
that non-responders tend to have elevated gene expres-
sion of interferon-stimulated genes (ISGs) as a part of
the IFN regulation pathway and this may have a predic-
tive value in HCV therapy [134–136]. Moreover, higher
protein kinase (PKR) mRNA levels in peripheral blood
mononuclear cells (PBMC) and the liver correlated withnon-response. In addition, non-response was associated
with weak changes in PBMC gene expression as
opposed to pronounced changes in treatment responders
[137,138]. Furthermore, single nucleotide polymor-
phisms (SNPs) of diﬀerent genes have been reported to
be associated with treatment outcome.
HFE gene polymorphisms (both the C282Y and the
H63D mutation) may positively inﬂuence response to
IFN therapy as has been demonstrated in recent clini-
cal trials [139–141]. The underlying mechanisms how-
ever, have not been clearly delineated. Interestingly,
in the study by Bonkovsky et al. presence of HFE
mutations were also positively associated with high
hepatic iron concentration, a factor inversely associated
with treatment response in other studies (see below)
[139].
In addition to the studies described above, several
other associations were described and these investiga-
tions may be useful for a more detailed understanding
of sensitivity and resistance to IFN-based antiviral
A. Kau et al. / Journal of Hepatology 49 (2008) 634–651 641therapy. However, current data on genetic polymor-
phisms are insuﬃcient for implementation in clinical
routine.
4.1.2. Histologic parameters
In chronic hepatitis C, ﬁbrosis progression is variable
and seems to be dependent on age and duration of infec-
tion [142]. Furthermore, the pathogenesis of liver dam-
age is thought to be largely mediated by the host
immune system but genetic predisposition, hepatic
comorbidity (i.e. hemochromatosis, HIV-coinfection)
and lifestyle factors (alcohol consumption, hepatic stea-
tosis) may worsen ﬁbrosis progression [143–148].
Staging. The presence of advanced liver ﬁbrosis and
cirrhosis has long been recognised to be associated with
lower response rates to IFN-based treatment [127].
Moreover, advanced ﬁbrosis and cirrhosis have been
shown to be major independent predictors of non-
response [149]. Furthermore, in a large study with
HCV genotypes 2 and 3 infection and a relatively high
rate of patients with cirrhosis [12] as well as in one very
large study including 4913 patients with HCV genotypes
1–3 infection [131] multivariate regression analyses iden-
tiﬁed the absence of cirrhosis as a predictor of SVR
(Table 3).
In the PEG IFN alfa-2a/RBV as well as PEG IFN
alfa-2b/RBV registration trials no signiﬁcant association
of liver cirrhosis with non-sustained virologic response
was observed in multilogistic regression analyses. How-
ever, direct comparison of patients with and without cir-
rhosis showed lower SVR rates in both studies.
Furthermore, in these studies the rates of patients with
liver cirrhosis were relatively low, which may explain
the lack of correlation with virologic response in the
multivariate analysis [6,10]. The same may be true for
the study of genotypes 2- and 3-infected patients andTable 3
Baseline predictors of SVR in chronic hepatitis C: histological parametersa
Baseline predictors Number of
patients
Genotype Single
p-value
Odds ratio
Staging
No or only portal ﬁbrosis 1744 1–6 0.003 1.6 (1.2–2.
Absence of bridging
ﬁbrosis or cirrhosis
1530 1–6 0.001 No data
1463 2,3 <0.001 2.15 (1.63–
224 2,3 n.s. No data
Cirrhosis vs. non-cirrhosis 1121 1–6 n.s. No data
4913 1,2,3 <0.0001 0.58 (0.47–
Steatosis
Steatosis <5% 224 2,3 0.012 No data
Absence of steatosis 1034 1,2, 4–6c <0.001 No data
a Based on multivariate analysis.
b (see Table 2). 95% conﬁdence interval.
c No correlation for HCV genotype 3; n.s., not statistically signiﬁcant.shortened treatment duration of 24 weeks with PEG
IFN 2b plus RBV [13] (Table 3).
Hepatic steatosis. The frequency of signiﬁcant steato-
sis in chronic hepatitis C ranges between 40% and 80%
depending on additive risk factors of fatty liver disease
[143,150–152]. In several studies it has been suggested
that the virus may directly cause steatosis. In addition,
steatosis is associated with an accelerated progression
of liver ﬁbrosis and HCV genotype 3 infection
[151,153,154]. In two large studies the absence of steato-
sis was strongly correlated with SVR in multivariate
analyses [13,152] (Table 3).
Hepatic iron concentration. The pathogenesis of hepa-
tic iron concentration (HIC) in chronic hepatitis C
remains unclear although heterozygosity for hereditary
haemochromatosis (i.e. C282Y heterozygosity) has been
discussed for HCV-associated iron overload [139,155].
Further studies have demonstrated a negative correla-
tion between hepatic iron accumulation and response
to standard IFN therapy, especially in genotype 1b-
infected individuals [156–164]. However, in more recent
trials HIC did not predict response to combination ther-
apy [165–167].
4.1.3. Virologic parameters
HCV baseline viral load. Although HCV RNA quan-
tiﬁcation was not shown to be predictive for the degree of
HCV-related liver injury or the progression of disease,
assessment of viral load before, during and after therapy
is an important tool for the prediction of treatment out-
come. A low baseline viral load (<600,000–800,000 IU/
ml or less) was shown to be an independent predictor
of SVR regardless of genotype in numerous studies
[6,12,13,127,130,131,168–170] (Table 4). Interestingly,
the eﬀect of viral load as a predictor was found to beb Therapy Reference
2) IFN/IFN 2b + RBV Poynard et al. [127]
IFN 2b + RBV/PEG IFN 2b + RBV Manns et al. [6]
2.81) PEG IFN 2a + RBV Shiﬀman et al. [12]
PEG IFN 2b + RBV Zeuzem et al. [13]
PEG IFN 2a+/RBV/IFN 2b + RBV Fried et al. [10]
0.73) PEG IFN 2b + RBV Jacobson et al. [131]
PEG IFN 2b + RBV Zeuzem et al. [13]
IFN 2b/PEG IFN 2b + RBV Poynard et al. [152]
Table 4
Baseline predictors of SVR in chronic hepatitis C: virologic factorsa
Baseline predictors Number of
patients
Genotype Single
p-value
Odds ratiob Therapy Reference
HCV Baseline viral load
Low baseline viral load 832 1–6 <0.001 No data IFN 2b/IFN 2b + RBV Poynard et al. [170]
1530 1–6 <0.0001 No data IFN 2b + RBV/PEG IFN 2b + RBV Manns et al. [6]
260 1–6 0.04 2.6 (1.4–5.0) IFN 2a + RBV/PEG IFN 2a + RBV Berg et al. [169]
HCV RNA level 224 2,3 0.026 No data PEG IFN 2b + RBV Zeuzem et al. [13]
455 1 <0.01 No data PEG IFN 2a + RBV Berg et al. [130]
4913 1,2,3 <0.0001 0.8 (0.71–0.84) PEG IFN 2b + RBV Jacobson et al. [131]
<600,000 IU/ml 1744 1–6 0.0001 1.9 (1.5–2.5) IFN/IFN 2b + RBV Poynard et al. [127]
235 1 0.0001 No data PEG IFN 2b + RBV Zeuzem et al. [168]
6400,000 vs.
>800,000 IU/ml
1463 2,3 <0.001 3.01 (2.15–4.20) PEG IFN 2a + RBV Shiﬀman et al. [12]
Genotype
Gt other than 1 1530 1–6 <0.0001 No data IFN 2b + RBV/PEG IFN 2b + RBV Manns et al. [6]
1121 1–6 <0.001 3.25 (2.09–5.12) PEG IFN 2a+/RBV/IFN 2b + RBV Fried et al. [10]
4913 1,2,3 <0.0001 2.29 (0.67–7.76) PEG IFN 2b + RBV Jacobson et al. [131]
1284 1–6 <0.001 5.4 (4.1–7.1) PEG IFN 2a + RBV Hadziyannis et al. [11]
Gt 2 or 3 1744 1–6 <0.0001 6.0 (4.6–7.8) IFN/IFN 2b + RBV Poynard et al. [127]
Gt 2 > gt 3 1463 2,3 < 0.001 1.88 (1.46–2.43) PEG IFN 2a + RBV Shiﬀman et al. [12]
a Based on multivariate analysis.
b 95% conﬁdence interval; n.s., not statistically signiﬁcant; gt, genotype.
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approximately 400,000 IU/ml a linear correlation with
SVR was shown, for higher HCV RNA levels relative
stable SVR rates without a signiﬁcant further decline
have been observed in PEG IFN alfa-2a/RBV-treated
patients [171]. However, due to signiﬁcant diﬀerences
of HCV RNA concentrations obtained with the diﬀerent
commercially available assays despite standardization to
IU absolute cut-oﬀ values for low or high HCV RNA
baseline concentrations are diﬃcult to deﬁne [172–174].
HCV genotype. HCV genotype is the most important
baseline predictor for response to interferon alfa-based
therapy. This has been demonstrated in numerous stud-
ies and generally HCV genotype 1-(4–6)-infected
patients are less likely to experience SVR than those
infected with other genotypes if treated for the same
duration [6,10–12,127,131] (Table 4). SVR rates for
genotype 1-infected patients ranged from 41% to 52%
after 48 weeks of PEG IFN plus RBV as opposed to
76–84% in genotypes 2 and 3 [6,10,11]. Forty-eight
weeks of combination therapy in genotype 4 patients
showed response rates at an intermediate level compared
to genotype 1 and genotypes 2 or 3, with SVR rates
between 65% and 72%, as recently described [175–177].
To date, no large randomized trials of genotypes 5-
and 6-infected patients have been conducted. However,
from the few patients included in the PEG IFN plus
RBV registration trials, it is believed that responses to
48 weeks of treatment are similar to genotype 1-SVR
rates. Furthermore, in a recent study signiﬁcant diﬀer-
ences between HCV genotypes 2 and 3 with higher
SVR rates in genotype 2-infected patients have beenshown [12] (Table 4). The underlying functional mecha-
nisms for lower SVR rates of the diﬀerent HCV geno-
types are unknown.
Other viral factors. Other viral factors associated with
SVR include the degree of viral quasi-species complexity
[178–180] and the number of mutations within speciﬁc
regions of the HCV genome (i.e. the NS5A region)
[181–183].
4.1.4. Biochemical parameters
Aminotransferase levels. Unlike chronic hepatitis B,
the association between baseline aminotransferase levels
and SVR in chronic hepatitis C is less clear-cut. In some
trials, baseline alanine aminotransferase (ALT) levels or
ALT quotient (baseline ALT value divided by ULN)
were not associated with treatment response in the mul-
tilogistic regression analysis [10,130]. However, in the
study by Shiﬀman et al. in HCV genotypes 2- and 3-
infected patients such a correlation was observed [12].
In addition, low pre-treatment serum gamma glutam-
yltransferase (GGT) levels were signiﬁcantly and inde-
pendently associated with SVR in multivariate
regression analysis with an odds ratio comparable to
HCV genotype [130,169,184] (Table 5). The pathoge-
netic background of GGT elevation in chronic hepatitis
C is not fully understood. However a close relationship
between serum GGT levels and hepatic steatosis,
advanced ﬁbrosis, and insulin resistance has been
described [185,186].
Other biochemical predictors. Raised serum ferritin is
another biochemical predictor associated with less
Table 5
Baseline predictors of SVR in chronic hepatitis C: biochemical parametersa
Baseline predictors Number of
patients
Genotype Single
p-value
Odds ratiob Therapy Reference
GGT
Low baseline
GGT level
455 1 <0.001 No data PEG IFN 2a + RBV Berg et al. [130]
153 2,3 <0.02 No data PEG IFN 2a + RBV von Wagner et al. [184]
260 1–6 <0.0001 5.7 (3.2–10.0) IFN 2a + RBV/PEG IFN 2a + RBV Berg et al. [169]
a Based on multivariate analysis.
b 95% conﬁdence interval.
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Furthermore, in a recent mouse model study, evidence
was given that HCV might be directly involved in the
development of insulin resistance and its associated
hyperinsulinemia [188]. Insulin resistance on the other
hand, is independently associated with poor treatment
response, especially in genotype 1-infected patients
[122,189–193]. In addition, insulin resistance has also
been implicated in the development of hepatic steatosis
which again is a poor treatment predictor as described
above [143,152,153].
4.2. Predictors during antiviral therapy
4.2.1. Viral kinetics
Viral kinetics have been analysed in a large number of
studies for prediction of treatment response and non-
response with the aim to establish algorithms for indi-
vidualized treatment durations [194–196].
During the ﬁrst week of interferon-based therapy, a
typically biphasic decay of viremia can be observed.
Rapid reduction of HCV-RNA within the ﬁrst 24–48 h
reﬂects the blocking of viral production with elimination
of free virions and the subsequent slower log-linear
decline has been considered to represent the clearance
of infected hepatocytes [195,197]. Although both phases
are associated with virologic response, viral kinetic
parameters of the second phase, i.e. the rate of infected
cell loss, have been particularly associated with sus-
tained response [194–204]. These observations, however,
are based on complex mathematical models and may
not be used in everyday clinical practice.
Assessment of response after 4 weeks of treatment. A
rapid viral response (RVR), determined as undetectableTable 6
On-treatment predictors of SVR in chronic hepatitis Ca
On-treatment predictors Number of patients Genotype Single p-va
Viral kinetics
after 4 weeks
RVR 740 1 <0.0001
428 2,3 No data
RVR vs. no RVR 1383 1–4 <0.0001
a Based on multivariate analysis.
b 95% conﬁdence interval.serum HCV-RNA at week 4 of therapy is increasingly
recognised as one of the most important independent
predictors of SVR (Table 6). In a recent retrospective
analysis of 1383 patients it was shown that achieving
RVR correlates with a high probability (86–100%) of
sustained virologic response to PEG IFN/RBV combi-
nation therapy, regardless of genotype [205]. In geno-
type 1-infected patients, treatment shortening
(24 weeks instead of 48 weeks) is feasible if low
(<600,000–800,000 IU/ml) baseline viral load and an
RVR is present. SVR rates were >75% in these patients
as reported in a number of studies involving both PEG
IFN alfa-2a- and PEG IFN alfa-2b-based therapy. This
more individualized treatment approach has been
approved by European regulatory authorities
[168,206,207] and may also be adopted for genotype 4-
infected patients [207,208].
In genotype 2/3-infected patients similar rules apply.
Several clinical trials have pointed out the possibility of
shortening treatment duration to 12–16 weeks instead of
24 weeks following an RVR [184,209–211]. However,
data from a recently published larger trial suggested that
treatment shortening to 16 weeks should be considered
for patients with an RVR and low baseline viral load
(<800,000 IU/ml) only [12]. This was recently approved
by regular authorities in the European Union. Cur-
rently, no data are available whether extension of treat-
ment duration in genotype 2/3-infected patients without
RVR may lead to increased SVR rates but prospective
trials are ongoing.
Assessment of response after 12 weeks of treatment.
For many years, early virologic response (EVR), deﬁned
as viral load decline P2 log10 or undetectable HCV-
RNA at week 12, used to be the mainstay of HCV on-lue Odds ratiob Therapy Reference
23.7 (9.1–61.7) PEG IFN 2a + RBV Jensen et al. [206]
4.2 (2.4–7.6) PEG IFN 2b + RBV Dalgard et al. [211]
7.5 (5.6–10.2) PEG IFN 2a + RBV Fried et al. [205]
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with a decline of less than 2 log10 HCV-RNA IU/ml
at week 12 have the chance of an SVR [10,212] and this
has led to the implementation of a stopping rule for
patients without EVR irrespective of genotype.
However, rates of SVR in genotype 1-infected
patients achieving an EVR are heterogeneous. By subdi-
viding EVR into complete EVR (HCV-RNA <50 IU/ml
at week 12) or partial EVR (>2 log10 drop in HCV-RNA
but still detectable [>50 IU/ml]), it may be possible to
further improve the prediction of patients likely to
achieve an SVR and allow for tailoring treatment dura-
tion accordingly.
It was recently shown that genotype 1-infected
patients with a complete EVR achieved high SVR rates
(68–84%) with PEG IFN/RBV combination therapy for
48 weeks, unlike patients with a partial EVR (2 log10
decline but still HCV-RNA positive at week 12) who
achieved an SVR of only 17–29% [130,205]. The authors
concluded that this particular group of slow responding
patients may beneﬁt from treatment extension to
72 weeks and this was also supported by other trials
[213–215]. Approximately 90% of patients with HCV
genotype 2/3 infection achieve a complete EVR and
no data are currently available on the management of
those with partial EVR.
Assessment of response after 24 weeks of treatment. A
signiﬁcant number of patients who pass the week 12
stopping rule with a decline of more than 2 log10 will
result HCV-RNA positive even at week 24 resulting in
failure to achieve SVR in 98–100% of instances. Hence,
treatment discontinuation irrespective of HCV genotype
is recommended in this situation [6,212,215]. On the
other hand, patients with HCV genotype 1-infection
who have detectable HCV-RNA at weeks 4 and/or 12,
and who subsequently have undetectable HCV-RNA at
week 24 (partial EVR) may beneﬁt from treatment exten-
sion to 72 weeks as discussed above, although SVR rates
in these patients remain relatively low [130,213–215].5. Conclusion
Pre- and on-treatment predictors are important tools
for successful treatment in chronic hepatitis B and C.
In chronic hepatitis B, predicting the response to
either (PEG) IFN or nucleos(t)ide therapies oﬀers the
advantage of optimal drug selection to improve treat-
ment outcomes. In addition, response predictors may
help deﬁne optimal treatment duration in HBeAg-posi-
tive patients and deﬁne those patients at risk of develop-
ing drug resistance to nucleos(t)ide compounds. For
HBeAg-positive patients, prediction is generally based
on HBeAg loss or seroconversion to anti-HBe while
for HBeAg-negative patients prediction is based onHBV DNA suppression at the end of treatment or at a
deﬁned follow-up.
Few demographic factors have been associated with
response to HBV treatment [51]. In one study younger
age and female gender were predictive of viral suppres-
sion at 24 weeks post-treatment in HBeAg-negative
patients treated with PEG IFN alfa-2a and/or LAM
[53]. Histologic factors predictive of response to IFN
or PEG IFN treatment were high grading and staging
scores in HBeAg-positive patients [9,54–58] but no cor-
relation could be found in patients with HBeAg-negative
status [53]. In addition, conﬂicting data exist for nucle-
os(t)ides for HBeAg-positive and no correlation was
found for HBeAg-negative patients [44,47,53,55,59].
Low baseline viral load levels are generally consid-
ered to be predictive of favourable virologic response
across all patients with chronic hepatitis B and treat-
ment regimens [9,44,47,53,54,57,59,66–72,85]. Further-
more, genotypes were important baseline factors in
(PEG) IFN treatment studies and HBeAg-positive
patients. The highest response rates were obtained in
patients with genotypes A and B in comparison with
genotypes D and C, respectively [31,69,76–79]. In
HBeAg-negative patients genotypes B and C were more
predictive of viral suppression at 24 weeks post-treat-
ment than genotype D in one study [53].
In nucleos(t)ide-treated patients some conﬂicting
data exist but generally no eﬀect of genotype on treat-
ment outcome was observed in HBeAg-positive and -
negative patients [72,82,85–87].
Finally, high baseline ALT levels were positively cor-
related with virologic response in (PEG) IFN-treated
patients, regardless of HBeAg status [31,53,66,68,69].
However, in the nucleos(t)ide trials conﬂicting data exist
concerning the importance of baseline ALT levels
[44,47,53,59,72,87,90].
In chronic hepatitis C sustained viral eradication may
be achieved in approximately 50% of patients following
PEG IFN plus RBV treatment [6,10]. For analysis of
treatment predictors in the present study, mainly large
pivotal trials with combination therapy of (PEG) IFN
and ribavirin have been included. The inﬂuence of diﬀer-
ences between the studies which may be attributed to the
use of standard IFN vs. PEG IFN, diﬀerent types of
(PEG) IFN, as well as diﬀerent doses of RBV and diﬀer-
ent treatment durations were not taken into account.
Positive demographic predictors of SVR in both
IFN- and PEG IFN/RBV-treated patients were Asian
and Caucasian ethnicity. The diﬀerence was detectable
in all studies with combination therapy for standard
treatment durations and seems to be restricted to geno-
type 1-infected patients [119,121–123,125,126,131].
Interestingly, female gender was predictive of SVR in
standard IFN-treated patients but not in the PEG
IFN-based approval studies when assessed by multivar-
iate analyses [6,10,127]. Furthermore, younger age was
A. Kau et al. / Journal of Hepatology 49 (2008) 634–651 645predictive of SVR across all genotypes and treatment
regimens [6,10,12,127] but inconsistent data for the cor-
relation of body weight and BMI with SVR were pub-
lished [6,10,12,13,130,131].
Important histologic parameters associated with SVR
were absence of advanced ﬁbrosis and no or little steatosis
in (PEG) IFN treatment regimens [12,13,127,131,152].
A correlation of ALT levels was not described in all
studies but low GGT levels seem to be highly signiﬁ-
cantly associated with SVR [130,169,184].
As is widely known, HCV genotype other than 1 and
low baseline viral load are the most important baseline
predictors of SVR [6,10–13,127,130,131,168–170]. Once
treatment has been initiated, monitoring of HCV
RNA decline has become an increasingly important tool
for the prediction of SVR [168,205,206,211]. In particu-
lar, RVR has been recognised as one of the most power-
ful predictors of SVR and, when assessed in
combination with baseline viral load, can be used to
identify patients for whom a shortened treatment course
is appropriate.References
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